COMPOSITION FOR DETECTING LHRH OR hCG/LH RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS
The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
1 . A composition comprising:
(a) a prostate, breast, ovarian, endometrial, pancreatic, hepatic, melanoma, kidney, gastrointestinal, lung, lymphoma or leukemia sample from a cancer patient in combination with a hormone polypeptide or hormone polypeptide analog that binds to LHRH- or hCG/LH receptors in a reaction mixture under conditions allowing the hormone or hormone analog to bind the LHRH- or hCG/LH receptors in the sample;
(b) a quantitative measurement of an amount of LHRH- or hCG/LH receptors in the sample that are bound to the hormone polypeptide or hormone polypeptide analog;
(c) a combination of cells obtained from the sample with a peptide comprising the cytotoxic sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG (SEQ ID NO:1) in a reaction mixture; and
(d) a quantitative measurement of the sensitivity of the cells in the sample to the cytotoxic sequence.
2 . The composition of claim 1 , wherein the quantitative measurement is an IC50 value.
3 . The composition of claim 1 , wherein the cytotoxic sequence is biotin-conjugated or fluorescein conjugated.
4 . The composition of claim 1 , wherein the hormone polypeptide or hormone polypeptide analog comprises one or more D-amino acids.
5 . The composition of claim 1 , wherein the hormone polypeptide or hormone polypeptide analog is biotin-conjugated or fluorescein-conjugated.
6 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the pancreatic cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
7 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the hepatic cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
8 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the melanoma sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
9 . The composition of claim 8 , wherein the melanoma sample comprises a melanoma of the eye sample.
10 . The composition of claim 9 , wherein the melanoma sample comprises a melanoma of the skin sample.
11 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the kidney cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
12 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the gastrointestinal sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
13 . The composition of claim 12 , wherein the gastrointestinal sample comprises a colon sample.
14 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the lung cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
15 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the lymphoma sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
16 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the breast cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
17 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the prostate cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.
18 . The composition of claim 1 , wherein the quantitative measurement of the amount of LHRH- or hCG/LH receptors in the reaction mixture is a designation of whether or not greater than 50% of the cells in the ovarian cancer sample express LHRH- or hCG/LH receptors and whether the cells in the pancreatic cancer sample have a sensitivity to the cytotoxic sequence of IC50 5.5 μM or less.